PDF(Pubmed)
Abstract：
Ovarian cancer (OC) is the deadliest gynaecological malignancy. Identifying new prognostic biomarkers is an important research field. Haemostatic components together with leukocytes can drive cancer progression while increasing the susceptibility to venous thromboembolism (VTE) through immunothrombosis. Unravelling the underlying complex interactions offers the prospect of uncovering relevant OC prognostic biomarkers, predictors of cancer-associated thrombosis (CAT), and even potential targets for cancer therapy. Thus, this study evaluated the expression of F3, F5, F8, F13A1, TFPI1, and THBD in peripheral blood cells (PBCs) of 52 OC patients. Those with VTE after tumour diagnosis had a worse overall survival (OS) compared to their counterparts (mean OS of 13.8 ± 4.1 months and 47.9 ± 5.7 months, respectively; log-rank test, p = 0.001). Low pre-chemotherapy F3 and F8 expression levels were associated with a higher susceptibility for OC-related VTE after tumour diagnosis (χ2, p < 0.05). Regardless of thrombogenesis, patients with low baseline F8 expression had a shorter progression-free survival (PFS) than their counterparts (adjusted hazard ratio (aHR) = 2.54; p = 0.021). Among those who were not under platelet anti-aggregation therapy, low F8 levels were also associated with a shorter OS (aHR = 6.16; p = 0.006). Moving forward, efforts should focus on external validation in larger cohorts.
摘要：
卵巢癌（OC）是最致命的妇科恶性肿瘤。识别新的预后标志物是一个重要的研究领域。止血成分与白细胞一起可以驱动癌症进展，同时通过免疫血栓形成增加对静脉血栓栓塞（VTE）的易感性。解开潜在的复杂相互作用提供了发现相关OC预后生物标志物的前景，癌症相关血栓形成（CAT）的预测因子，甚至是癌症治疗的潜在目标。因此，这项研究评估了52例OC患者外周血细胞（PBCs）中F3，F5，F8，F13A1，TFPI1和THBD的表达。与肿瘤诊断后的VTE患者相比，其总生存期（OS）较差（平均OS为13.8±4.1个月和47.9±5.7个月，分别；对数秩检验，p=0.001)。化疗前F3和F8低表达水平与肿瘤诊断后OC相关的VTE的易感性更高(χ2,p<0.05)。不管血栓形成,基线F8低表达患者的无进展生存期(PFS)较低(校正风险比(aHR)=2.54;p=0.021).在那些没有接受血小板抗聚集治疗的人中，低F8水平也与较短的OS相关(aHR=6.16;p=0.006).往前走,努力应该集中在更大队列的外部验证上。
